Myasthenia Gravis Treatment: A Leading Driver Behind Myasthenia Gravis Treatment Market Surges In Response To Escalating Disease Prevalence Market Expansion in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Myasthenia Gravis Treatment Industry Market Size Be by 2025?
In the last few years, the market size for myasthenia gravis treatment has witnessed robust growth. The market is projected to expand from $1.55 billion in 2024 to $1.66 billion in 2025, yielding a compound annual growth rate (CAGR) of 7.3%. Factors such as the use of cholinesterase inhibitors, thymectomy procedures, immunosuppressant therapies, the introduction of plasma exchange, and patient advocacy have contributed to the growth experienced in the previous period.

What's the Long-Term Growth Forecast for the Myasthenia Gravis Treatment Market Size Through 2029?
The market size for treating myasthenia gravis is predicted to experience substantial growth in the coming years, reaching a value of $2.26 billion by 2029, with a compound annual growth rate (CAGR) of 8.0%. The driving forces behind this growth during the projected period can be ascribed to various factors such as the advent of biologics and monoclonal antibodies, the development of genetic and precision medicine, innovations in immune modulators, neuroprotective methods, and the use of biosimilar medications. Key trends expected to shape the market during the forecast period include the introduction of digital therapeutics, shared research initiatives, a focus on patient-centered approaches, the application of real-world evidence, and long-term monitoring for safety.

View the full report here:
https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report

What Are the Key Growth Drivers Fueling the Myasthenia Gravis Treatment Market Expansion?
An increase in the occurrence of myasthenia gravis is projected to drive the expansion of the market for its treatment. Myasthenia gravis is an autoimmune neuromuscular disorder that results in fatigue and weakness in the skeletal muscles. The treatment of this disease involves providing medical care and support to the patient, helping them fight myasthenia gravis. This increase in myasthenia gravis cases is therefore enhancing sales in its treatment market. In January 2022, the National Organization for Rare Disorders, a non-profit US-based entity working with rare disease patients, reported that myasthenia gravis had a projected prevalence of 14-40 per 100,000 individuals in the United States. Moreover, in April 2024, information published by the American Journal of Managed Care, a peer-reviewed U.S. journal, revealed that, based on an average of 1,800 myasthenia gravis diagnoses per year, the yearly incident rate was estimated at 4.32 cases per 100,000 individuals, with an incidence rate of 2.46 cases per 100,000 person-years. Thus, the rising incidence of myasthenia gravis is fueling the growth of the market for its treatment.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp

What Are the Key Trends Driving Myasthenia Gravis Treatment Market Growth?
A primary trend prevalent in the myasthenia gravis treatment market is product advancement. To retain market share, leading firms are emphasizing new treatment developments. In October 2023, significant news came from UCB Pharma, a pharmaceutical firm based in Belgium when they announced that the US Food and Drug Administration (FDA) endorsed their product, Zilucoplan. This product, approved for use in adult patients who are tested positive for anti-acetylcholine receptor (AChR) antibodies, provides a new option for managing generalized myasthenia gravis (gMG). gMG is a condition marked by muscle weakness as a result of an autoimmune response. The standout feature of ZILBRYSQ is that it is self-administered and is a once-a-day subcutaneous complement C5 inhibitor. This presents an advantageous substitute to the customary intravenous therapies used in treating gMG.

How Is the Myasthenia Gravis Treatment Market Segmented?
The myasthenia gravis treatment market covered in this report is segmented -

1) By Treatment: Medication, Surgery, Other Treatments
2) By Medication Type: Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types
3) By End-Use: Hospitals, Clinics, Other End-Uses

Subsegments:
1) By Medication: Anticholinesterase Agents, Immunosuppressants, Monoclonal Antibodies, Corticosteroids
2) By Surgery: Thymectomy
3) By Other Treatments: Plasmapheresis, Intravenous Immunoglobulin (IVIg), Supportive Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11980&type=smp

Which Companies Are Leading the Charge in Myasthenia Gravis Treatment Market Innovation?
Major companies operating in the myasthenia gravis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics

Which Regions Are Leading the Global Myasthenia Gravis Treatment Market in Revenue?
North America was the largest region in the myasthenia gravis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11980

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.